Investment Newsletters

QURE stock

Uniqure NV (QURE) Is Getting the Street All Fired Up on Its Gene Therapy Candidate in Hemophilia B; Oppenheimer Spotlights Efficacy/Safety Strength

Hartaj Singh believes QURE trots out an upper hand advantage with AMT-061.

Julie Lamb — October 20, 2017, 10:07 AM EDT

Cowen Shines Light on Uniqure NV (QURE) as the Latter Advances Padua Variant AMT-061 into Phase 3

Uniqure NV is back in the race for a hemophilia B gene therapy.

Corey Williams — October 19, 2017, 3:28 PM EDT